Four Ways to Cash in on the $29.6 Billion Psychedelic ‘Shroom Boom

The number of stocks in the psychedelics space, no pun intended, is expanding like all good universes.

There are already more than 50 publicly traded companies pursuing the billions in new market opportunities in the hallucinogen-based treatment market – a “New Biotech” opportunity I like to refer to as the ‘Shroom Boom.

A lot of these companies are innovative cousins to conventional biotech firms. Like their better-known counterparts, these upstarts are pursuing new drugs, compounds, therapies, and treatment protocols, to arrest or even cure mental illnesses, substance abuse, pain, PTSD, and even chronic brain disorders. The big difference: These ‘Shroom Boom ventures are incorporating psychedelics in their research and trials.

I’ve also identified “pick-and-shovel” companies whose path to sales-and-profits relies on sourcing and manufacturing psychedelics or building infrastructure, like clinics and training therapists.

Here are four companies I like. Two cover the research, trials, and biotech potential of psychedelics. The other two are pick-and-shovels plays that have ID’d innovative ways to apply their trade on this new trend.

In the entire realm of biotech, it’s one of the most-exciting and biggest-profit opportunities I’m watching.

Forget Pot Stocks – It’s Time to Cash-In on the Psychedelics ‘Shroom Boom

I came of age in the late ’60s and early ’70s, which means I’m no stranger to recreational drugs, from pot to psychedelics. Like, I’ve seen things, man – and could tell you some stories. And I was so fascinated by what I saw that I got with the program, and dug deep into the story behind the story.

LSD was still legal. Research was going full bore. And I understood these drugs had promise – real promise.

That all ended in October 1968, when the U.S. made it illegal to possess the hallucinogen. And thanks to that, the research slowly died.

But psychedelics are making a comeback. And I’m groovin’ on all the hip research and FDA trials, and the crazy number of publicly traded companies chasing riches in the psychedelics rainbow.

Can you dig it? You should. There’s evidence psychedelics have the potential to arrest – and maybe even cure – a host of disorders from depression to brain trauma. And if these drugs work – and if you’re into the right stocks – you could end up on the trip of your life, and watch as your portfolio gets high … and I mean really high, man.

If you’re watching the markets and looking at this “new biotech,” you’re no doubt hearing about the tremendous promise of the marijuana legalization, the cannabis market – and the pot-stock boom.

Maybe you missed the pot-stock run the first time around. Or maybe you can’t bring yourself to invest in something in something that’s been maligned so much for so many years.

Don’t sweat it – because here’s the heavy truth: The real opportunity is with psychedelics.

Call it the Shroom Boom.

And I’m going to lay it on you here…

How to Play BABA Calls and Tap into Another Triple-Digit Profit Opportunity

Last Tuesday, I mentioned I liked buying the MRNA June 18, 2021 $165/170 Put Spread to take advantage of what looked like an opportunity for a quick reversal in Moderna, Inc. (NasdaqGS:MRNA).

By Thursday, just two days later, shares of MRNA had dropped as much as 23%, and the MRNA June 18, 2021 $165/170 Put Spread had gained more than 400%

I sure hope you were following along!

The Latest from the Watchlist – Vaccine Stock Flops, Chinese Market Giants, and the Movie Theater Revival

Now I don’t mean to say, “I told you so,” but Varney & Co. didn’t call me the “Man Who Calls It All” for nothing. Just as I predicted a few months back, Pfizer (PFE) stands to lose its COVID-19 vaccine patents and their company’s profitability is about to tank. Hard.

That’s leaves us a wide opening to make some serious profits with its downfall, but that’s not all on my watchlist today.

Early this morning, you should have gotten my watchlist update. Those will be coming in hot every Monday before the opening bell, so make sure to keep your eyes peeled!

If you missed it, don’t worry. You can read all about my favorite stocks for the week here.

Or, just click the video below because I am back with yet another video to take an even deeper dive into these stocks. PFE may be on its way out, but two other heavy-hitting Chinese stocks, NIO and BABA, are going to take off before the year is out.

So, let’s get started…

3 Sells, 2 Holds, and 1 BUY on Today’s Biggest Tech Movers

Tech stocks own the market, but that doesn’t mean you should go blindly into them. That’s what most people will do – but you shouldn’t.

Putting the hype before the horse means you’ll almost always wind up with losers disguised as the next Amazon. So, in today’s BS.H, you’ll hear about three tech stocks that run the gauntlet from the good, the bad, and the exceptionally ugly. I go over their profits, their debts, and whether they’re fit to buy, sell, or hold.

Just click the video below to watch…

Options Tuesday: Taking Profits Off of Moderna’s Tower of Terror

With COVID-19 vaccination programs rolling along, it might well be assumed that any stock tied to vaccinations is on a one-way trip higher.

Not so fast. There’s that whole thing about “assuming,” and I think you know what they say…

This Week’s BS.H – What to Do with Two of the Biggest Pot Stocks with Legalization Afoot

With legalization around the corner for so many states in the U.S., several of you were asking: “To buy or not to buy?”

That is the question… A few years back I would have given a resounding heck no. But I have to say, I’m starting to change my mind about two of the biggest pot stocks on the market right now.

And I’ll tell you why in today’s BS.H, where I tell you what to buy, sell, or hold.

With this Ag-Stock “Basket” You’ll Kick Food-Price Inflation Right in the Teeth

Been to the grocery store lately? Then you know that food prices are surging.

The U.S. Federal Reserve refers to that as “inflation” – a clinical bit of jargon that fails to capture the sticker-shock pain your family feels every time you wheel a shopping cart into the checkout line.

Central bankers also tell us this inflation is “transitory.”

But I’m here to tell you that it’s not.

Food prices have been rising for almost two years; they really accelerated during the pandemic and have never looked back.

And it’s only going to get worse.

Thanks to surging demand both here and overseas, the multi-year “Megadrought” in the southwestern United States, an ongoing “overhang” from the COVID-19 pandemic, and foreign-trade gamesmanship from Beijing, agricultural commodities are soaring in price.

Just look at the “Big Three” of ag commodities – wheat, corn, and soybeans.

Wheat, the key ingredient in flour, bread, cookies, pastries, and pasta was already at a seven-year high – and just logged its biggest weekly climb in almost two years on expectations of strong global demand and lower production from Russia, the world’s No. 1 exporter. Cold temperatures have hit winter wheat crops in the Southern Plains and Central states of America. And, according to FranceAgriMer’s cereal crop report, France’s wheat and barley crops have deteriorated, too.

Corn, which goes into cereals, snack foods, soft drinks, and other sweet foods, is already at its highest level since 2013 – thanks to lousy weather that’s delayed planting in such crucial growing regions like the United States and Brazil. The U.S. Department of Agriculture said that cold weather could slow the germination of newly seeded corn. U.S. corn crop was 8% planted as of Apr 18. The crops from the 2020 harvest have also been deteriorating.

Finally, we have soybeans, used in soymilk, tofu, and as protein for cattle – meaning they influence meat prices. Soybeans are brushing up against eight-year highs. Tightening global grain and vegetable oil supplies just ignited the biggest weekly rise in soybean futures since May 2019. Meanwhile, the Chinese are trying to import more soybeans to meet strong demand from that country’s livestock sector. And shipments from Brazil – the world’s top exporter – dropped to their lowest level since January 2017. The Farm Bureau says cool, dry weather in the Midwest could hurt soybean crops, although U.S. farmers plan to plant 87.6 million acres of soybeans this year – the most since 2018 – to capitalize on that demand and the higher prices the supply squeeze will create.

So, yes that basket of groceries you’re bringing home to your family will continue to take bigger and bigger bites out of your household budget.

Here’s why I’m sharing this all with you today.

I’m decoding the ag-commodity surge, explaining the inflationary spike still to come, and identifying some of the companies that stand to be the biggest beneficiaries. You can buy these shares, ride along as they profit – and make enough to transform food-price inflation into a non-factor in your household.

And I mean starting today. Starting right now…

Options Tuesday: COIN May Be Down… But It’s Not Out

Coinbase’s stock came out of the gate hot to trot, but it’s been acting more like a dog than a pony since its debut.

Monday Watchlist: EVs are Hot… And I’ve Got the Plays to Match

Now that the markets have opened, it’s more important than ever that you see this.

You’ve had some time to go through the Weekly Watchlist I sent yesterday – which you can still see by clicking here. Today, I’m taking a deep dive into EVS and the plays that could make it big this week.

So, grab a pen and paper. You might want to write these down.

Just click on the video below to get all the details…

Cheap Stock Millionaire: A $7 Pick With 10X Potential

Here’s what I’ve got for you today…

It’s a company with a lock on government contracts across the globe – just when Biden’s White House is looking to sink trillions into infrastructure.

It’s a company whose earnings are projected to explode tenfold over the next year – dangling a potential “10X gain” for investors shrewd enough to stake their claim now.

But here’s the best part of this stock-market story…

I’m talking about a company whose stock is trading at less than eight bucks a share.

That’s right – a $7 stock.

Welcome to the world – and the power – of low-priced stocks.

Not penny stocks. Not junk stocks.

But cheap stocks.

More specifically: Low-priced stocks, where the under-$10 share prices make it easy for you to grab big stakes – and where those big stakes can give you 10x gains on the stock and the same on your portfolio.

In yesterday’s Total Wealth, we outlined the very real “10X” allure of single-digit-sticker-price stocks – and even showed you how to find them.

Today we’re showing you one to buy…

You’re In!

Thank you for joining the Total Wealth community. You’re all set to receive everything on the Coinbase trade for Tuesday. Just keep an eye on your inbox, and I’ll be there soon. To make sure you are able to receive …

Continue reading

Buy These Stocks for Pennies and Turn Them into Dollars… Lots of Dollars

Take-Two Interactive Software Inc. (NasdaqGS:TTWO) as the gaming gorilla behind such mega-hits as the Grand Theft Auto, NBA, Mafia, and Red Dead Redemption franchises – and a firm with a market value of more than $20 billion and a share-price trading peak up near $215.

There was a time, however, when Take-Two was an under-the-radar “cheap stock” – indeed one that was trading for less than 10 bucks a share.

For folks keeping track at home, that’s a 2,050% windfall from a single-digit-share-price stock.

And Take-Two isn’t the only one like this.

There’s also Patrick Industries Inc. (NasdaqGS:PATK), a building products company that’s now worth more than $2 billion and whose shares trade at about $90 each.

There was a time when Patrick was worth less than $25 million – and its shares were trading at about $1.20.

For investors who played this cheap-stock play, that’s a windfall of 7,100%.

Or how about LendingTree Inc. (NasdaqGS:TREE) – the fintech leader that’s pretty much a household name these days. This go-to lender recently had a $3 billion market value and a stock price up around $220.

But there was also a time when LendingTree was worth a minuscule $60 million – with a stock price down around $5.50.

From that point to today, we’re talking about a total return of about 3,800%.

Now, I’m not sharing these stories just because I love an underdog.

If you want to make money – real money – look at these single-to-low digit stock plays.

And this isn’t just me talking: Research by academics and institutional players backs up everything I say.

If you look at the 50 biggest winners of the last decade, 39 of them started out as small- to mid-cap plays.

And quite a few of them were also low-priced (as in cheap) stocks, all with great fundamentals – like the ones we’re talking about here – indeed, the same ones I seek out for you folks here at Total Wealth.

In this two-day special report, we’re going to show you how it’s done.

Today, we’re going to show you why cheap stocks can be so hot.

Tomorrow we’ll get you started with a $7 stock to play.

You see, cheap stocks aren’t trash – in fact, they can be stock-market gold….

Options Tuesday: Let’s Play the Bond Market Rally

For Options Tuesday, we’re playing the bond market rally.

You know, the rally that in about 10 days just took the 10-year Treasury from a 1.79% yield to 1.54%.

Yep, the bond market rally that crescendoed last week right when economic data showed the fewest new unemployment claims since March and retail sales skyrocketing 9.8%.

That bond market rally.

Weekly Watchlist: Welcome to Earnings Season

Now that the markets have opened, it’s more important than ever that you see this.

You’ve had some time to go through the Weekly Watchlist I sent yesterday – which you can still see by clicking here. Today, I’m taking a deep dive into these companies, and the state of the market. Everything is elevated and, while I’m still bullish, we need to stay on our toes.

Just click here to get all the details…